Production Strategies for Antibody Fragment Therapeutics

Microbial systems such as E. coli and yeasts are the most effective systems for the production of antibody fragments.

ABSTRACT

Full-length antibodies have captured a significant fraction of the sales volume and value of the biopharmaceuticals market. With increasing knowledge, however, it has been recognized that full-length antibodies may not always be necessary or even desirable. Antibody fragments provide the opportunity for new therapeutic possibilities. Moreover, antibody fragments have the potential for simpler, high-yielding production processes, which can translate into a lower manufacturing cost-of-goods and extended therapeutic benefit. This article discusses the …